Stockreport

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On-Demand Vardenafil for Pulmonary Hypertension

Gossamer Bio, Inc.  (GOSS) 
Last gossamer bio, inc. earnings: 3/24 07:00 am Check Earnings Report
PDF - RT234 is an investigational inhaled, as needed (PRN) vardenafil formulation for PAH and PH-ILD, where no on demand treatments exist -- Capital-efficient structure with [Read more]